GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 20.50
-0.30 (-1.44%)
At close: Feb 11, 2026
GeneReach Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -148.46 | -118.73 | -166.27 | 221.34 | 376.62 | 257.28 |
Depreciation & Amortization | 72.79 | 73.73 | 68.03 | 64.28 | 59.24 | 51.33 |
Other Amortization | 1.26 | 1.01 | 0.86 | 0.89 | 0.77 | 0.5 |
Loss (Gain) From Sale of Assets | 28.38 | 28.17 | 1.39 | -1.7 | -0.41 | -0.5 |
Asset Writedown & Restructuring Costs | -1.54 | - | - | - | - | - |
Loss (Gain) From Sale of Investments | 13.87 | 2.57 | 2.5 | 3.7 | 3.81 | 5.19 |
Loss (Gain) on Equity Investments | - | - | - | - | - | 0.04 |
Stock-Based Compensation | 2.1 | - | - | - | - | - |
Provision & Write-off of Bad Debts | -6.12 | -4.65 | 21.43 | -1.13 | 5.06 | 1.99 |
Other Operating Activities | -2.8 | -1.35 | -66.17 | -65.61 | 14.8 | 58.93 |
Change in Accounts Receivable | 9.34 | -16.97 | 12.04 | 138.08 | -31.15 | -93.49 |
Change in Inventory | -1.03 | 14.8 | 124.59 | 16.07 | -91.29 | -156.1 |
Change in Accounts Payable | -0.95 | 1.39 | -0.24 | -6.04 | -5.44 | 4.55 |
Change in Unearned Revenue | -2.43 | -0.55 | -2.84 | -11.49 | 13.17 | - |
Change in Other Net Operating Assets | 4.34 | -2.63 | -33.99 | -0.73 | 3.82 | 40.1 |
Operating Cash Flow | -31.28 | -23.22 | -38.67 | 357.63 | 348.99 | 169.82 |
Operating Cash Flow Growth | - | - | - | 2.48% | 105.51% | - |
Capital Expenditures | -6.46 | -7.12 | -23.53 | -49.87 | -19.56 | -62.2 |
Sale of Property, Plant & Equipment | 0.84 | 0.17 | - | 3.93 | 1.97 | 0.82 |
Sale (Purchase) of Intangibles | -3.86 | -1.34 | -3.82 | -0.59 | -1.36 | -2.67 |
Investment in Securities | 59.13 | -62.75 | -221.54 | - | 3.85 | - |
Other Investing Activities | 1.63 | 0.84 | -1.02 | -1.48 | -26.61 | -44.85 |
Investing Cash Flow | 51.28 | -70.21 | -249.91 | -48.01 | -41.7 | -108.9 |
Short-Term Debt Issued | - | 137 | 55 | - | - | 51 |
Long-Term Debt Issued | - | - | - | - | 198 | 30 |
Total Debt Issued | 254 | 137 | 55 | - | 198 | 81 |
Short-Term Debt Repaid | - | -70 | - | - | -2 | - |
Long-Term Debt Repaid | - | -47.58 | -201.94 | -19.35 | -8.82 | -5.95 |
Total Debt Repaid | -303.4 | -117.58 | -201.94 | -19.35 | -10.82 | -5.95 |
Net Debt Issued (Repaid) | -49.4 | 19.42 | -146.94 | -19.35 | 187.18 | 75.05 |
Common Dividends Paid | - | - | - | -208.94 | -143.67 | - |
Other Financing Activities | -0.02 | -15.99 | -68.95 | - | -0.04 | - |
Financing Cash Flow | -66.73 | 3.43 | -215.89 | -228.28 | 43.48 | 75.05 |
Foreign Exchange Rate Adjustments | -15.95 | -16.5 | -27.37 | 3.84 | -1.01 | 0.69 |
Net Cash Flow | -62.68 | -106.5 | -531.84 | 85.18 | 349.75 | 136.66 |
Free Cash Flow | -37.74 | -30.35 | -62.21 | 307.76 | 329.43 | 107.62 |
Free Cash Flow Growth | - | - | - | -6.58% | 206.11% | - |
Free Cash Flow Margin | -17.52% | -14.70% | -27.59% | 41.03% | 32.55% | 12.56% |
Free Cash Flow Per Share | -0.66 | -0.53 | -1.08 | 5.19 | 5.62 | 1.87 |
Cash Interest Paid | 6.85 | 5.54 | 4.56 | 4.58 | 5.26 | 3.82 |
Cash Income Tax Paid | 6.37 | 5.4 | 14.03 | 117.39 | 78.3 | 21.84 |
Levered Free Cash Flow | -85.43 | -68.75 | 22.55 | 262.91 | 331.25 | 46.48 |
Unlevered Free Cash Flow | -81.15 | -65.04 | 26.15 | 267.04 | 335.16 | 48.86 |
Change in Working Capital | 9.26 | -3.96 | 99.56 | 135.88 | -110.9 | -204.95 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.